儿童COVID-19相关疾病住院患者抗凝血栓预防的共识建议与研究优先方向
该科学声明由20名儿童血液科与儿童重症医学科医师参与调查(应答率90%),并结合文献综述形成共识。建议对COVID-19相关疾病(包括MIS-C)住院儿童中D-二聚体显著升高或存在医院相关VTE叠加临床危险因素者,在无禁忌时使用低剂量低分子肝素皮下注射每日两次,并尽可能联合序贯加压装置机械预防;对临床不稳定或严重肾损伤者建议持续静脉输注普通肝素。声明同时提出通过多中心合作试验明确儿童COVID-19的VTE风险与抗凝预防策略安全性和有效性的研究优先方向。
要点
- COVID-19相关疾病(含MIS-C)住院儿童若D-二聚体显著升高或存在医院相关VTE叠加临床危险因素,专家共识建议(弱推荐)皮下低剂量低分子肝素每日两次抗凝预防。
- 上述低分子肝素预防应在无禁忌证时使用,并尽可能联合序贯加压装置进行机械性血栓预防。
- 对临床不稳定或严重肾损伤的COVID-19相关疾病住院儿童,专家共识建议(弱推荐)持续静脉输注普通肝素作为抗凝预防。
- 儿童COVID-19相关疾病住院患者抗凝预防的高质量证据仍然匮乏,声明将随高质量证据出现而更新。
- 未来研究优先方向包括通过多中心合作试验明确儿童COVID-19(含MIS-C)VTE风险与危险因素、评估抗凝预防策略的安全性和有效性。
适用人群与场景
- 因COVID-19相关疾病住院的儿童,包括多系统炎症综合征儿童(MIS-C)。
- 亚组:D-二聚体水平显著升高或存在医院相关VTE叠加临床危险因素的住院儿童,为低分子肝素预防的适用人群。
- 亚组:临床不稳定或存在严重肾损伤的住院儿童,为普通肝素持续静脉输注预防的适用人群。
处置流程与药物剂量
- 对D-二聚体显著升高或存在医院相关VTE叠加临床危险因素的COVID-19相关疾病(含MIS-C)住院儿童,在无禁忌证时,专家共识建议(弱推荐)皮下注射低剂量低分子肝素每日两次作为抗凝血栓预防。
- 上述低分子肝素预防应尽可能联合序贯加压装置进行机械性血栓预防。
- 对临床不稳定或严重肾损伤的COVID-19相关疾病住院儿童,专家共识建议(弱推荐)持续静脉输注普通肝素作为抗凝血栓预防。
红旗征与不能漏的情况
- 临床不稳定:专家共识建议(弱推荐)此类患儿改用普通肝素持续静脉输注而非低分子肝素。
- 严重肾损伤:专家共识建议(弱推荐)此类患儿改用普通肝素持续静脉输注而非低分子肝素。
研究设计与关键结果
- 研究类型:科学声明,基于对20名儿童血液科与儿童重症医学科医师的问卷调查及文献综述形成共识。
- 调查应答率为90%。
- 共识建议(弱推荐):对D-二聚体显著升高或存在医院相关VTE叠加临床危险因素的COVID-19相关疾病(含MIS-C)住院儿童,在无禁忌证时皮下注射低剂量低分子肝素每日两次,并尽可能联合序贯加压装置机械预防。
- 共识建议(弱推荐):对临床不稳定或严重肾损伤的COVID-19相关疾病住院儿童,持续静脉输注普通肝素作为抗凝预防。
- 研究优先方向:通过多中心合作试验明确儿童COVID-19(含MIS-C)VTE风险与危险因素,并评估抗凝预防策略的安全性和有效性。
证据类型、等级与局限
- 证据类型:共识声明(专家意见),基于20名专家调查(应答率90%)及文献综述。
- 证据等级:共识推荐,原文使用「we suggest」表述(弱推荐)。
- 局限:原文指出高质量证据仍然匮乏(paucity of high-quality evidence)。
对床旁实践的改变
- 对COVID-19相关疾病(含MIS-C)住院儿童,若D-二聚体显著升高或存在医院相关VTE叠加临床危险因素且无禁忌证,专家共识建议(弱推荐)皮下低剂量低分子肝素每日两次联合机械预防。
- 对临床不稳定或严重肾损伤的COVID-19相关疾病住院儿童,专家共识建议(弱推荐)持续静脉输注普通肝素替代低分子肝素。
- 声明强调目前儿童COVID-19抗凝预防的高质量证据匮乏,建议通过多中心合作试验进一步评估策略安全性和有效性。
指南或共识出处
- 儿童COVID-19相关疾病住院患者抗凝血栓预防共识建议(Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness),发表于J Thromb Haemost。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Observational studies indicate that children hospitalized with COVID-19-related illness, like adults, are at increased risk for venous thromboembolism (VTE). A multicenter phase 2 clinical trial of anticoagulant thromboprophylaxis in children hospitalized with COVID-19-related illness has recently been initiated in the United States. To date, there remains a paucity of high-quality evidence to inform clinical practice world-wide. Therefore, the objective of this scientific statement is to provide consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses, and to identify priorities for future research.
METHODS: We surveyed 20 pediatric hematologists and pediatric critical care physicians from several continents who were identified by Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee leadership as having experience and expertise in the use of anticoagulant thromboprophylaxis and/or the management of COVID-19-related illness in children. A comprehensive review of the literature on COVID-19 in children was also performed.
RESULTS: Response rate was 90%. Based on consensus of expert opinions, we suggest the administration of low-dose low molecular weight heparin subcutaneously twice-daily as anticoagulant thromboprophylaxis (in the absence of contraindications, and in combination with mechanical thromboprophylaxis with sequential compression devices, where feasible) in children hospitalized for COVID-19-related illness (including the multisystem inflammatory syndrome in children [MIS-C]) who have markedly elevated D-dimer levels or superimposed clinical risk factors for hospitalassociated VTE. For children who are clinically unstable or have severe renal impairment, we suggest the use of unfractionated heparin by continuous intravenous infusion as anticoagulant thromboprophylaxis. In addition, continued efforts to characterize VTE risk and risk factors in children with COVID-19, as well as to evaluate the safety and efficacy of anticoagulant thromboprophylaxis strategies in children hospitalized with COVID-19-related illness (including MIS-C) via cooperative multicenter trials, were identified among several key priorities for future research.
CONCLUSION: These consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses and priorities for future research will be updated as high-quality evidence emerges.
参考来源
- Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020. PMID: 33174388. doi:10.1111/jth.15073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。